{"id":"NCT02932267","sponsor":"Galderma R&D","briefTitle":"Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne","officialTitle":"Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide 2.5% in Moderate to Severe Acne in Dark Skin Phototype Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-02","primaryCompletion":"2018-01-10","completion":"2018-01-10","firstPosted":"2016-10-13","resultsPosted":"2019-11-15","lastUpdate":"2021-02-18"},"enrollment":50,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Adapalene 0.3% / BPO 2.5% gel","otherNames":["Epiduo Forte / Tactupump gel"]}],"arms":[{"label":"Adapalene / BPO gel","type":"EXPERIMENTAL"}],"summary":"This is a multicenter open-label, prospective study in subjects with dark skin from one of the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American and with moderate to severe acne vulgaris on the face.\n\nAll eligible subjects will receive Adapalene 0.3% - BPO 2.5% gel (Epiduo Forte/TactuPump Forte) once daily on whole face.\n\nThe purpose of this trial is to evaluate subject reported outcomes with the combination of Adapalene 0.3% - BPO 2.5%, Epiduo Forte / TactuPump Forte gel, after 16 weeks of treatment of moderate to severe acne in dark skin phototypes (IV to VI).","primaryOutcome":{"measure":"Subject 's Overall Satisfaction With Study Treatment Via a Satisfaction Questionnaire","timeFrame":"At week 12","effectByArm":[{"arm":"Adapalene / BPO Gel","deltaMin":36,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":3,"countries":["United States","Mauritius","Singapore"]},"refs":{"pmids":["31251543"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Headache","Pyrexia","Post inflammatory pigmentation change","Pruritus"]}}